Inhibikase Therapeutics (IKT) Accumulated Depreciation & Amortization (2022 - 2025)
Inhibikase Therapeutics (IKT) has disclosed Accumulated Depreciation & Amortization for 4 consecutive years, with $117224.0 as the latest value for Q3 2025.
- Quarterly Accumulated Depreciation & Amortization rose 133.71% to $117224.0 in Q3 2025 from the year-ago period, while the trailing twelve-month figure was $117224.0 through Sep 2025, up 133.71% year-over-year, with the annual reading at $56725.0 for FY2024, 86.27% up from the prior year.
- Accumulated Depreciation & Amortization for Q3 2025 was $117224.0 at Inhibikase Therapeutics, up from $93537.0 in the prior quarter.
- The five-year high for Accumulated Depreciation & Amortization was $170970.0 in Q2 2023, with the low at $1681.0 in Q3 2022.
- Average Accumulated Depreciation & Amortization over 4 years is $54854.8, with a median of $43590.0 recorded in 2024.
- The sharpest move saw Accumulated Depreciation & Amortization skyrocketed 1320.88% in 2023, then plummeted 74.5% in 2024.
- Over 4 years, Accumulated Depreciation & Amortization stood at $6723.0 in 2022, then soared by 352.97% to $30453.0 in 2023, then surged by 86.27% to $56725.0 in 2024, then surged by 106.65% to $117224.0 in 2025.
- According to Business Quant data, Accumulated Depreciation & Amortization over the past three periods came in at $117224.0, $93537.0, and $69379.0 for Q3 2025, Q2 2025, and Q1 2025 respectively.